All documents in the system

  1. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBnet consensus statement - 2014

  2. South African National Tuberculosis Management Guidelines - 2014

  3. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis - 2013

  4. Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis - 2013

  5. Guidelines for the management of tuberculosis in children - 2013

  6. Guidelines for the management of tuberculosis, human immunodeficiency virus and sexually-transmitted infections in correctional facilities - 2013

  7. MDR, XDR, TDR tuberculosis: ominous progression - 2012

  8. Implementing Collaborative TB-HIV Activities: A Programmatic Guide - 2012

  9. DR-TB drugs under the microscope - 2011 March

  10. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource- constrained settings - 2011

  11. Botswana TB/HIV Policy Guidelines - 2011

  12. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 update - 2011

  13. The Global Plan to Stop TB - 2011

  14. Use of interferon-gamma release assays in support of TB diagnosis - 2011

  15. Treatment of Tuberculosis: Guidelines for National Programmes - 2010

  16. Guidelines for Tuberculosis Preventative Therapy among HIV individuals of South Africa - 2010

  17. Guidelines for Management of Drug-Resistant Tuberculosis in South Africa - 2010

  18. Latent Tuberculosis Infection: A Guide for Primary Health Care Providers - 2010

  19. Advocacy Strategy for Adoption and Dissemination on the Policy on TB Control in Health Care Facilities, Congregate Settings and Households: Recommended Actions at International and National Level - 2010

  20. Rapid Advice: Treatment of Tuberculosis in Children - 2010

  21. Review of the National Tuberculosis Programme in Ukraine - 2010

  22. Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection in United States - 2010

  23. Guidance for national tuberculosis and HIV programmes on the management of tuberculosis in HIV-infected children: Recommendations for a public health approach - 2010

  24. Management of Tuberculosis: A Guide to the Essentials of Good Clinical Practice - 2010

  25. Guidance on Ethics of Tuberculosis Prevention, Care and Control - 2010

  26. Desk-guide for diagnosis and management of TB in children - 2010

  27. Revised National Tuberculosis Control Programme DOTS-Plus Guidelines - 2010

  28. South African National Tuberculosis Management Guidelines - 2009

  29. Management of MDR-TB: A field guide - 2009

  30. A guide to Monitoring and Evaluation for Collaborative TB/HIV Activities - 2009

  31. Natural Ventilation for Infection Control in Health-Care Settings - 2009

  32. Monitoring and Evaluation Toolkit: HIV, TB and Malaria and Health Systems Strenghtening - 2009

  33. Environmental Controls for Tuberculosis : Basic Upper-Room Ultraviolet Germicidal Irradiation Guidelines for Healthcare Settings - 2009

  34. Policy on TB Control in Health Care Facilities, Congregate Settings and Households - 2009

  35. Guidelines for Surveillance of Drug Resistant in Tuberculosis - 2009

  36. Plan to Combat Extensively Drug-Resistance Tuberculosis: Recommendations of the Federal Task Force - 2009

  37. Pediatric Infectious Disease Referral Guidelines: Tuberculosis in Children - 2009

  38. Updated Guidelines for the Use of Nucleic Acid Amplification Tests in the Diagnosis of Tuberculosis - 2009

  39. Management of Latent TB Infection in Children and Adolescents: A Handbook for the Primary Care Provider - 2009

  40. The National Tuberculosis Health Sector Strategic Plan for Ghana - 2009

  41. Guidelines on management of Leprosy and Tuberculosis in Kenya - 2009

  42. MOST for TB: Management and Organizational Sustainability Tool for National TB Control Programs - 2009

  43. Tuberculosis: Information for Health Care Providers - 2009

  44. National Framework For Joint HIV/TB Collaborative Activities - 2009

  45. Drug Resistant Tuberculosis Guidelines and Manual for Swaziland - 2008

  46. Implementing the WHO Stop TB Strategy: Handbook for National TB Control Programmes - 2008

  47. WHO/The Union Monograph on TB and Tobacco Control - 2008

  48. Surveillance of Communicable Diseases in European Union: Long Term Strategy - 2008

  49. Managing TB Medicines at the Primary Level - 2008

  50. Managing Pharmaceuticals and Commodities: A Guide for National Tuberculosis Programs - 2008

  51. Framework Action Plan to fight tuberculosis in European Union - 2008

  52. The National Infection Prevention and Control Policy for TB, MDRTB and XDRTB - 2007

  53. Tuberculosis Strategic Plan for South Africa 2007-2011 - 2007

  54. National Policy Guidelines for HIV/TB Collaborative Activities - 2007

  55. Tuberculosis Infection Control in the Era of Expanding HIV Care and Treatment: Addendum to WHO Guidelines for the Prevention of Tuberculosis in Health Care Facilities in Resource-limited Settings - 2007

  56. Infection prevention and control of epidemic- and pandemic-prone acute respiratory diseases in health care — WHO interim guidelines - 2007

  57. Tuberculosis Care and Control in Refugee and Displaced Populations: An Interagency Field Manual - 2007

  58. Best Practice for the Care of Patients with Tuberculosis: A Guide for Low-Income Countries - 2007

  59. Priorities for Bacteriology Services in Low-Income Countries - 2007

  60. Implementation of HIV/TB Collaborative Activities for Ghana: Technical Policy and Guidelines - 2007

  61. Guideline for the Clinical Management of TB and HIV Co-infection in Ghana - 2007

  62. Canadian Tuberculosis Standards - 2007

  63. Environmental Control Best Practices: Guidelines to Reduce TB Transmission in Homeless Shelters and Drop-In Centres - 2007

  64. Prevention and Control of Tuberculosis in Correctional and Detention Facilities: Recommendations from CDC - 2006

  65. International Standards for Tuberculosis Control - 2006

  66. Guidelines for Implementing TB-HIV Collaborative Activities in Kenya: What health workers need to know - 2006

  67. Guidance for national tuberculosis programmes on the management of tuberculosis in children - 2006

  68. Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Healthcare Settings - 2005

  69. Technical and Operational Guidelines for Tuberculosis Control - 2005

  70. A Tuberculosis Guide for Specialist Physicians - 2004

  71. Stopping Tuberculosis in England: An action plan - 2004

  72. Guidelines for Implementing Collaborative TB and HIV Programme Activities - 2003

  73. Guidelines for Environmental Infection Control in Healthcare Facilities - 2003

  74. European framework to decrease the burden of TB/HIV - 2003

  75. Guidelines for the investigation and follow-up of individuals under medical surveillance for tuberculosis after arriving in Canada - 2003

  76. Guidelines for Tuberculosis Control in New Zealand - 2003

  77. Treatment of the Patient with TB: Guidelines for Collaborting with Community Physicians - 2003

  78. Guidelines for Workplace TB Control Activities - 2003

  79. Guidelines for the Treatment of Tuberculosis - 2002

  80. General Recommendations on Immunization - 2002

  81. Interventions for Tuberculosis Control and Elimination - 2002

  82. A Guide for Tuberculosis Treatment Supporters - 2002

  83. An Expanded DOTS Framework for TB - 2002

  84. Guidelines for initiating a school-based directly observed therapy program - 2002

  85. National Strategic Plan for TB Control in Australia - 2002

  86. Management, Control and Prevention of Tuberculosis Guidelines for Health Care Providers - 2002

  87. Guide for the Procurement of Anti-Tuberculosis Drugs - 2001

  88. Tuberculosis in the Workplace - 2001

  89. Good Practice in Legislation and Regulations for TB Control: An Indicator of Political Will - 2001

  90. Guidelines for Targeted Tuberculosis Testing and Treatment of Latent Tuberculosis Infection - 2000

  91. Technical Guide: Sputum Examination for Tuberculosis by Direct Microscopy in Low-Income Countries - 2000

  92. Pharmaceutical Management for Tuberculosis (PMTB) Assessment Manual - 2000

  93. Guidelines for the Prevention of Tuberculosis in Health Care Facilities in Resource-limited Settings - 1999

  94. Guidelines for the Management of Adverse Drug Effects of Antimycobacterial Agents - 1998

  95. Enforcement Procedures and Scheduling for Occupational Exposure to Tuberculosis - 1996

  96. Guidelines for Preventing the Transmission of Tuberculosis in Canadian Health Care Facilities and Other Institutional Settings - 1996

  97. Policy Guidelines for Collaborative TB and HIV Services for Injecting and Other Drug Users: An Integrated Approach

  98. Recommendations for the Screening and Prevention of TB in Patients with HIV and the Screening for HIV in TB Patients and thier Contacts

  99. Response by Medicines Control Council to letter by Global TB CAB on bedaquiline

  100. TB CAB Open Letter to Otsuka Re: Pharmacokinetic Studies, Paediatric Studies, and Compassionate Use of Delamanid

  101. TB CAB Open Letter to Janssen Pharmaceutical Companies of Johnson & Johnson Re: Pharmacokinetic Studies, Paediatric Studies, and Compassionate Use of Bedaquiline

  102. TB CAB Open Letter to the Food and Drug Administration Re: Crucial Regulatory Harmonization on Endpoints and Pharmacokinetic Studies for Tuberculosis Drug Development

  103. TB CAB Open Letter to the European Medicines Agency Re: Conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783)

  104. Postdoctoral fellowship in TB diagnostic research

  105. Letter Re: Changes in the ART guidelines

  106. Memorandum Re: New criteria for initiating HIV-positive TB patients on lifelong antiretroviral therapy (ART) irrespective of CD4 count

  107. Round table discussion: Activist engagement and community involvement in TB research

  108. Janssen's Response to TB CAB Letter 12 June 2012 regarding Pharmacokinetic Studies, Paediatric Studies, and Compassionate Use of Bedaquiline

  109. Otsuka's Response to TB CAB Letter regarding Pharmacokinetic Studies, Paediatric Studies, and Compassionate Use of Delamanid

  110. EMA's response to TB CAB letter regarding conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783)

  111. Termination of the use of streptomycin for re-treatment cases

  112. TAG: Aspiring to Zero Symposium

  113. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study

  114. Treatment of tuberculosis: have we turned the corner?

  115. The 43rd Union World Conference on Lung Health will tackle issues from multidrug-resistant TB to tobacco control and raise the profile of lung disease

  116. MSF and TAG symposium: NGO and civil societies' role in sustainable approaches for scaling up DR-TB programmes

  117. AfroCAB concept note

  118. Advanced TB Diagnostic Research

  119. Presenting the European Forum for TB Innovation: innovative thinking in progressing towards TB elimination in Europe

  120. Call for video testimonies

  121. Former TB patients: effective community engagement and lessons learnt

  122. Advocacy Corner at Union World Conference

  123. 4th Union Asia Pacific Region Conference on Lung Health, conference brochure

  124. Community consultation: A Silent Crisis: Tuberculosis Drug Shortages in the U.S.

  125. Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis

  126. Approval of novel TB drug celebrated - with restraint

  127. Post-2015 tuberculosis strategies in a pre-2015 world

  128. TB Laboratory Biosafety Manual

  129. Community-based tuberculosis prevention and care: Why and how to get involved

  130. Same-day diagnosis and treatment of tuberculosis

  131. WHO and the future of disease control programmes

  132. TAG: Public comment, Re: Urgent recommendations to address and resolve ongoing shortages of tuberculosis drugs in the United States

  133. EMA's response to TB CAB letter regarding the filing of the drugs delamanid and bedaquiline for market approval.

  134. International childhood TB training course, South Africa, 30 September - 4 October, 2013

  135. Global week of action against EU’s FTAs, 9-15 April 2013

  136. Free Heartland TB Intensive course, San Antonio, Texas, May 7-10, 2013

  137. Press release: Condemned to death came to the Cabinet of Ministers

  138. MDR-TB webinar in Russian: Basics of MDR-TB Program Management, 14 – 30 May 2013

  139. TB CAB open letter to Indian Prime Minister on EU-India FTA

  140. TB CAB open letter to Indian Health Minister on EU-India FTA

  141. TAG, TB CAB, India CAB open letter Re: Marketing and use of QuantiFERON-TB Gold for active TB in India and high TB burden countries

  142. Lal Path Lab Memo

  143. RNTCP Serology Ad

  144. Drug-resistant tuberculosis: time for visionary political leadership

  145. The Global Drug Facility and its role in the market for tuberculosis drugs

  146. Qiagen's response to the open letter sent by TAG, TB CAB and India CAB re: Marketing and use of QuantiFERON-TB Gold for active TB in India and high TB burden countries

  147. TAG symposium: Cascades: Improving TB Care

  148. Antiretroviral therapy for prevention of HIV and TB: A promising intervention but not a panacea

  149. Open letter to Indian Prime Minister: Stop the TB drug stockouts

  150. Fact sheet on TB drug stockouts

  151. Civil society demonstration, Wednesday, June 26, 2013

  152. Zero TB Deaths: A Pipedream? - Part 1

  153. Zero TB Deaths: A Pipedream? - Part 2

  154. Civil Society Memorandum

  155. Open letter to Sanofi: Reduce rifapentine cost and increase research funding

  156. TAG, TB CAB, India CAB open letter to Immunoshop Re: Marketing and use of TB Platinum for active TB in India and high TB burden countries

  157. 44th Union World Conference on Lung Health will focus on “Shared air, safe air?”

  158. Novel pediatric delivery systems for second-line anti-tuberculosis medications: a case study

  159. Sentinel Project: Workshop on inclusion of children in TB surveys, Union Conference, October 31, 2013

  160. Media coverage, TB drug stockouts in India, 2013

  161. Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data

  162. 'I cry every day’: experiences of patients co-infected with HIV and multidrug-resistant tuberculosis

  163. TAG, TB CAB open letter to Sequella Re: Further research into sutezolid urgently needed for tuberculosis

  164. Promoting affordable and quality tuberculosis testing in India

  165. TAG, TB CAB open letter to Alere Re: Responsible marketing and access plans for Alere’s Determine TB-­LAM antigen test for active TB

  166. Invitation - Stop TB Partnership event, 31 October, Paris, France

  167. Provisional agenda - Stop TB Partnership event, 31 October, Paris, France

  168. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-ra

  169. Administering second-line antituberculous medications to children with multidrug-resistant tuberculosis: A qualitative study

  170. Demostration, Fix the patent laws, South Africa, October 17, 2013

  171. CRAG open letter to Sanofi: Request for an official Sanofi response before escalation

  172. TAG symposium “Cascades: Improving TB Care”: Welcome - Colleen Daniels, TAG

  173. TAG symposium “Cascades: Improving TB Care”: Three Epiphanies - Paul Farmer, Harvard Medical School & PIH

  174. TAG symposium “Cascades: Improving TB Care”: Learning from the HIV experience: Continuum of Care Initiative - Ken Castro, U.S. Centers for Disease Control and Prevention

  175. TAG symposium “Cascades: Improving TB Care”: Can zero TB deaths become a reality? Lessons from Tomsk, Russian Federation - Salmaan Keshavjee, Harvard Medical School & PIH

  176. TAG symposium “Cascades: Improving TB Care”: Know your epidemic - David Dowdy, Johns Hopkins University

  177. TAG symposium “Cascades: Improving TB Care”: Patient centered approaches to cure - Jigna Rao, Patient Advocate

  178. TAG symposium “Cascades: Improving TB Care”: New Drugs, New Regimens, New Opportunities for MDR-TB - Jen Cohn, MSF

  179. WHO's 2013 global report on tuberculosis: successes, threats, and opportunities

  180. TB CAB, CRAG, TAG open letter to Otsuka, Re: Urgent appeal to initiate delamanid compassionate use program

  181. PRIFTIN PRICE REDUCTION NOTICE

  182. Who Makes Money on Epidemics of HIV/AIDS and Tuberculosis in Ukraine

  183. Open letter to Sanofi: Appreciation for commitment by Sanofi U.S. to lower the price of rifapentine

  184. TB CAB, TAG open letter to Cepheid Re: GeneXpert machine and Xpert MTB/RIF cartridge pricing, extended warranties and business in Russia and the People’s Republic of China

  185. Improving the health of the tuberculosis drug pipeline

  186. Call for Nominations - GLI Core Group Membership

  187. TB CAB, TAG public comment on Guidance for industry on pulmonary tuberculosis: Developing drugs for treatment

  188. GCTA Application Form 2014: INDIVIDUAL MEMBERSHIP

  189. GCTA Application Form 2014: NON-INDIVIDUAL MEMBERSHIP

  190. GCTA Constituency Charter (October 2013)

  191. TB CAB, GRAG, TAG open letter to AstraZeneca Re: Request to ensure continued investment in tuberculosis

  192. Otsuka's response to TB CAB, CRAG, TAG open letter regarding delamanid compassionate use program

  193. Open letter to Otsuka: continued concerns about delamanid's accessibility

  194. AstraZeneca: Response to TB CAB, CRAG, TAG open letter

  195. Otsuka and The Union announce Global TB Research & Innovation Award

  196. World TB Day 2014: finding the missing 3 million

  197. Smoking increases risk of recurrence after successful antituberculosis treatment: a population-based study

  198. Standards for TB Care in India (STCI), 1st edition, 2014

  199. International Standards for TB care (ISTC) 3rd edition, 2014

  200. Engage! brochure

  201. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates

  202. soniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial

  203. Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings?

  204. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial

  205. November 2014 conference: Developing a rights-based approach to TB: Call for papers

  206. TB CAB open letter: Ensuring the fair administration of the Kochon Prize

  207. Guidelines for Management of Drug-Resistant Tuberculosis in South Africa

  208. Flier: Ancient enemy, modern imperative: A time for greater action against tuberculosis

  209. Invitation AIDS 2014 Melbourne - Networking Zone: Should HIV activists be speaking louder about TB?

  210. Developing a Rights-Based Approach to Prevention and Treatment of Tuberculosis in India

  211. CALL FOR PAPERS: Developing a Rights-Based Approach to TB

  212. How to hinder tuberculosis control: five easy steps

  213. Letter from community groups to regulators regarding bedaquiline phase III trial design

  214. Virtual scientific workshop

  215. Working towards an HIV vaccine

  216. Tuberculosis drug discovery: Lessons learned and future prospects

  217. A rough guide to spotting bad science

  218. Open letter to Janssen: Reducing the price of bedaquiline

  219. Open letter to Janssen: Reducing the price of bedaquiline

  220. Open letter to Janssen: Reducing the price of bedaquiline

  221. TB CAB, TAG open letter to Janssen regarding the FDA approval of bedaquiline

  222. Understanding barriers to rifapentine use in U.S. tuberculosis programs to inform pricing advocacy

  223. Janssen's response to open letter calling on the company to reduce the price of bedaquiline

  224. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial

  225. Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis

  226. Assessment of the novel T-cell activation marker—tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study

  227. EMA Response to letter dated 28 July 2014

  228. Union Letter from Civil Society

  229. Civil society severely concerned with the Union's scholarship programme for the 45th Union World Conference on Lung Health

  230. Civil society severely concerned with the Union's scholarship programme for the 45th Union World Conference on Lung Health

  231. Janssen's response to open letter calling on the company to reduce the price of bedaquiline

  232. Letter to regulators re STREAM design from Community

  233. EMA answer to letter to regulators re STREAM 26.9.2014

  234. NA Union RPT Poster 19Feb2014

  235. P Stoffels letter BDQ pricing

  236. Assessment of the novel T-cell activation marker—tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study

  237. Community Corner at Union 2014

  238. Social protection and tuberculosis control in 21 European countries, 1995—2012: a cross-national statistical modelling analysis

  239. #CoughUpTheTBMoney: Civil society calls for tripling of money for TB research

  240. Activists urge Otsuka to provide access to TB drug

  241. Otsuka action, press release in Japanese

  242. UChicago TB Conference Call for Papers

  243. Rights-Based Approach to TB - University of Chicago Center in Delhi - Concept Note

  244. Abstract: Tuberculosis Drug Discovery, Lessons Learned and Future

  245. Abstract: Working Towards an HIV Vaccine

  246. Flyer

  247. DR-TB patients, activists demand registering generic linezolid, 14.10.2014

  248. Medicines Control Council's answer to TB CAB open letter on urgent need for compassionate use of bedaquiline for XDR-TB and pre-XDR-TB in South Africa.

  249. How a new funding model will shift allocations from the Global Fund to Fight AIDS, Tuberculosis and Malaria

  250. Global TB CAB Meeting Report Arlington, US 2011

  251. Global TB CAB Meeting Notes Union Kuala Lumpur 2012

  252. Global TB CAB Meeting Notes New Delhi 2013

  253. Global TB CAB Meeting Notes Union Paris 2013

  254. Global TB CAB Meeting Notes New York 2014

  255. Advocacy Strategy for Adoption

  256. Implementation of HIV/TB Collaborative Activities for Ghana: Technical Policy and Guidelines

  257. National Framework For Joint HIV/TB Collaborative Activities

  258. Surveillance of Communicable Diseases in European Union: Long Term Strategy

  259. Technical Guide: Sputum Examination for Tuberculosis by Direct Microscopy in Low-Income Countries

  260. MOST for TB: Management and Organizational Sustainability Tool for National TB Control Programs

  261. Stopping Tuberculosis in England: An action plan

  262. Technical and Operational Guidelines for Tuberculosis Control

  263. Global TB CAB ToR

  264. Valneva announces publication of first Phase II data of tuberculosis vaccine candidate formulated with IC31® adjuvant

  265. Tuberculosis in pregnancy: an estimate of the global burden of disease

  266. Open letter to South African Medical Schemes re: covering linezolid

  267. Open letter to South African Medical Schemes re: covering linezolid

  268. Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios

  269. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug

  270. Timing, rates, and causes of death in a large South African tuberculosis programme

  271. Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: A stepped-wedge cluster-randomized trial

  272. CRAG: A Protocol Review Companion for Activists

  273. Activism on rifapentine pricing: removing cost barriers to improve the uptake of tuberculosis research innovations

  274. Multidrug-resistant tuberculosis around the world: what progress has been made?

  275. Drug-resistance mechanisms and tuberculosis drugs

  276. Shortening treatment of tuberculosis: lessons from fluoroquinolone trials

  277. Tuberculosis as a cause or comorbidity of childhood pneumonia in tuberculosis-endemic areas: a systematic review

  278. Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study

  279. Tuberculosis vaccines: Time for a global strategy

  280. TAG open letter to the Global Plan Development Task Force

  281. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial

  282. Effect of diabetes on tuberculosis control in 13 countries with high tuberculosis: a modelling study

  283. Symposium: Re-inventing adherence: Patient-centered approaches to drug-resistant TB and HIV treatment

  284. Implementing a molecular test to diagnose pulmonary tuberculosis in Brazil: a case study

  285. Letter to The Union re TB Language

  286. Joint Partners Forum registration form

  287. Joint Partners Forum preliminary agenda

  288. 2015 EML process

  289. Call to action: Accelerate access to DR-TB drugs

  290. Tuberculosis diagnostics in 2015: Landscape, priorities, needs, and prospects

  291. Tuberculosis diagnostics in 2015: Landscape, priorities, needs, and prospects

  292. Call to action: Accelerate access to DR-TB drugs

  293. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly random

  294. Briefing document: Treating drug-sensitive TB in India: Implementation of daily therapy with fixed-dose combinations

  295. Sputum culture conversion as a prognostic marker for endof-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies

  296. Scaling up multidrug-resistant tuberculosis care in China

  297. Transforming the diagnosis of tuberculosis: an editorial board member’s opinion at the 15th year of Expert Review of Molecular Diagnostics

  298. Innovations in tuberculosis diagnostics: Progress and translational challenges

  299. Access to new medications for the treatment of drug-resistant tuberculosis: Patient, provider and community perspectives

  300. ECDC: Expert Opinion on the introduction of new drugs for tuberculosis control in the EU/EEA

  301. Open Letter to WHO: Time to report preventive TB therapy for children

  302. Supplementary appendix

  303. Riga Declaration

  304. Newsletter: Childhood tuberculosis update

  305. Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculo

  306. Burden of tuberculosis at post mortem in inpatients at a tertiary referral centre in sub-Saharan Africa: a prospective descriptive autopsy study

  307. Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial

  308. The End TB Strategy: India can blaze the trail

  309. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial

  310. TB CAB, TAG open letter to the Global Plan Development Task Force

  311. Support for extension of transitional period and waivers of least developed countries on TRIPS Agreement

  312. Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial

  313. Letter from TB community re: intellectual property rights to sutezolid

  314. WHO response: Recording and reporting of preventive TB therapy in children

  315. Open letter to WHO: Recording and reporting of preventive TB therapy in children

  316. Jim O’Neill sets out plan to overhaul the global antibiotics pipeline

  317. Treatment of drug-resistant TB with new and repurposed medications: A supplemental field guide for nurses

  318. The Trans-Pacific Partnership — is it bad for your health?

  319. The use of delamanid in the treatment of multidrug-resistant tuberculosis

  320. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis

  321. International Standards for TB care (ISTC) 3rd edition, 2014

  322. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis (2013)

  323. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 update (2011)

  324. Treatment of Tuberculosis: Guidelines for National Programmes (2010)

  325. Management of MDR-TB: A field guide

  326. WHO/The Union Monograph on TB and Tobacco Control (2008)

  327. Tuberculosis Care and Control in Refugee and Displaced Populations: An Interagency Field Manual (2007)

  328. A Guide for Tuberculosis Treatment Supporters (2002)

  329. An Extended DOTS framework for Tuberculosis (2002)

  330. Botswana TB/HIV Policy Guidelines (2011)

  331. Tuberculosis: Information for Health Care Providers (2009)

  332. ECDC: Expert Opinion on the introduction of new drugs for tuberculosis control in the EU/EEA (2015)

  333. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBnet consensus statement (2014)

  334. Management of contacts of MDR TB and XDR TB patients (2012)

  335. Guideline for the Clinical Management of TB and HIV Co-infection in Ghana (2007)

  336. Standards for TB Care in India (STCI), 1st edition, 2014 (2014)

  337. Revised National Tuberculosis Control Programme DOTS-Plus Guidelines (2010)

  338. Guidelines for the Clinical and Operational Management of Drug-Resistant Tuberculosis (2013)

  339. Management of Tuberculosis: A Guide to the Essentials of Good Practice (2010)

  340. Best Practice for the Care of Patients with Tuberculosis: A Guide for Low-Income Countries (2007)

  341. Priorities for Bacteriology Services in Low-Income Countries (2007)

  342. International Strategy for Tuberculosis Care (2006)

  343. Guide for the Procurement of Anti-Tuberculosis Drugs (2001)

  344. Guidelines for the management of Drug Resistant Tuberculosis in Kenya (2010)

  345. Guidelines on management of Leprosy and Tuberculosis in Kenya (2009)

  346. National Tuberculosis Management Guidelines (2014)

  347. Guidelines for the management of tuberculosis in children (2013)

  348. Guidelines for Management of Drug-Resistant Tuberculosis in South Africa (2013)

  349. Guidelines for the management of tuberculosis, human immunodeficiency virus and sexually-transmitted infections in correctional facilities (2013)

  350. South African National Tuberculosis Management Guidelines (2009)

  351. Drug Resistant Tuberculosis Management Guidelines (2008)

  352. Latent Tuberculosis Infection: A Guide for Primary Health Care Providers (2013)

  353. Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis (2013)

  354. Plan to Combat Extensively Drug-Resistance Tuberculosis: Recommendations of the Federal Task Force (2009)

  355. Managing TB Medicines at the Primary Level (2008)

  356. Managing Pharmaceuticals and Commodities: A Guide for National Tuberculosis Programs (2008)

  357. Treatment of the Patient with TB: Guidelines for Collaborating with Community Physicians (2003)

  358. Guidelines for the Treatment of Tuberculosis (2002)

  359. Guidelines for Targeted Tuberculosis Testing and Treatment of Latent Tuberculosis Infection (2000)

  360. Guidelines for the Management of Adverse Drug Effects of Antimycobacterial Agents (1998)

  361. Enforcement Procedures and Scheduling for Occupational Exposure to Tuberculosis (1996)

  362. Roadmap for Childhood Tuberculosis (2013)

  363. Guidance for national tuberculosis and HIV programmes on the management of tuberculosis in HIV-infected children: Recommendations for a public health approach (2010)

  364. Rapid Advice: Treatment of Tuberculosis in Children (2010)

  365. Guidance for national tuberculosis programmes on the management of tuberculosis in children (2006)

  366. National Guidelines For The Management Of Tuberculosis In Children (2012)

  367. Investigation and control of tuberculosis incidents affecting children in congregate settings (2013)

  368. Desk-guide for diagnosis and management of TB in children (2010)

  369. Management of Latent Tuberculosis in Children and Adolescents: A Handbook for the Primary Care Provider (2009)

  370. Guidelines for Initiating a School-Based Directly Observed Therapy Program (2002)

  371. Guidelines on the management of latent tuberculosis infection (2014)

  372. The Global Plan to Stop TB (2011-2015)

  373. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings (2011)

  374. Advocacy Strategy for Adoption and Dissemination on the Policy on TB Control in Health Care Facilities, Congregate Settings and Households (2010)

  375. Guidance on Ethics of Tuberculosis Prevention, Care and Control (2010)

  376. Natural Ventilation for Infection Control in Health-Care Settings (2009)

  377. Policy on TB Control in Health Care Facilities, Congregate Settings and Households (2009)

  378. Implementing the WHO Stop TB Strategy: Handbook for National TB Control Programmes (2008)

  379. Infection prevention and control of epidemic- and pandemic-prone acute respiratory diseases in health care — WHO interim guidelines (2007)

  380. Tuberculosis Infection Control in the Era of Expanding HIV Care and Treatment: Addendum to Guidelines for the Prevention of Tuberculosis in Health Care Facilities in Resource-limited Settings (2007)

  381. Guidelines for the Prevention of Tuberculosis in Health Care Facilities in Resource-limited Settings (2007)

  382. Guidelines for Workplace TB Control Activities (2003)

  383. Good Practice in Legislation and Regulations for TB Control: An Indicator of Political Will (2001)

  384. Guidelines for the Prevention of Tuberculosis in Health Care Facilities in Resource-limited Settings (1999)

  385. Management, Control and Prevention of Tuberculosis Guidelines for Health Care Providers (2002)

  386. National Strategic Plan for TB Control in Australia (2002)

  387. Environmental Control Best Practices: Guidelines to Reduce TB Transmission in Homeless Shelters and Drop-In Centres (2007)

  388. Framework Action Plan to fight tuberculosis in European Union (2008)

  389. European framework to decrease the burden of TB/HIV (2003)

  390. The National Tuberculosis Health Sector Strategic Plan for Ghana (2009-2013)

  391. Technical and Operational Guidelines for Tuberculosis Control (2005)

  392. Interventions for Tuberculosis Control and Elimination (2002)

  393. Guidelines for Tuberculosis Control in New Zealand (2003)

  394. National Strategic Plan on HIV, STIs and TB 2012-2016 (2012)

  395. Guidelines for Tuberculosis Preventative Therapy among HIV individuals of South Africa (2010)

  396. Tuberculosis Strategic Plan for South Africa 2007-2011 (2007)

  397. The National Infection Prevention and Control Policy for TB, MDRTB and XDRTB (2007)

  398. Stopping Tuberculosis in England: An Action Plan (2004)

  399. Latent Tuberculosis Infection: A Guide for Primary Health Care Providers (2010)

  400. MOST for TB: Management and Organizational Sustainability Tool for National TB Control Programs (2009)

  401. Prevention and Control of Tuberculosis in Correctional and Detention Facilities: Recommendations from CDC (2006)

  402. Guidelines on Preventing the Transmission of Mycobacterium tuberculosis in Healthcare Settings (2005)

  403. Guidelines on Environmental Infection Control in Healthcare Facilities (2003)

  404. General Recommendations on Immunization (2002)

  405. Tuberculosis in the Workplace (2001)

  406. Xpert MTB/RIF implementation manual (2014)

  407. Policy update: Xpert MTB/RIF assay for the diagnosis of pulmonary and extra-pulmonary TB in adults and children (2013)

  408. Rapid Implementation of Xpert MTB/RIF diagnostic test (2011)

  409. Policy statement: Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle- income countries (2011)

  410. Use of interferon-gamma release assays in support of TB diagnosis (2011)

  411. Technical Guide: Sputum Examination for Tuberculosis by Direct Microscopy in Low-Income Countries (2000)

  412. Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection in United States (2010)

  413. Updated Guidelines for the Use of Nucleic Acid Ampflication Test in the Diagnosis of Tuberculosis (2009)

  414. A Guide to Monitoring and Evaluation for Collaborative TB/HIV Activities (2009)

  415. Guidelines for Surveillance of Drug Resistance in Tuberculosis (2009)

  416. Guidelines for the Investigation and Follow-up of Individuals Under Medical Surveillance for Tuberculosis After Arriving in Canada (2003)

  417. Review of the National Tuberculosis Programme in Ukraine (2010)

  418. Surveillance of Communicable Diseases in European Union: Long Term Strategy (2008)

  419. Monitoring and Evaluation Toolkit: HIV, TB and Malaria and Health Systems Strenghtening (2009)

  420. Pharmaceutical Management for Tuberculosis (PMTB) Assessment Manual (2005)

  421. Policy Guidelines for Collaborative TB and HIV Services for Injecting and Other Drug Users (2008)

  422. Guidelines for Implementing Collaborative TB and HIV Programme Activities (2003)

  423. Recommendations for the Screening and Prevention of TB in Patients with HIV and the Screening for HIV in TB Patients and thier Contacts (2002)

  424. Implementation of HIV/TB Collaborative Activities for Ghana: Technical Policy and Guidelines (2007)

  425. National Framework For Joint HIV/TB Collaborative Activities (2009)

  426. Implementing Collaborative TB-HIV Activities: a Programmatic Guide (2012)

  427. Guidelines for Implementing TB-HIV Collaborative Activities in Kenya: What health workers need to know (2006)

  428. National Policy Guidelines for HIV/TB Collaborative Activities (2007)

  429. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis (2013)

  430. Guidelines for surveillance of drug resistance in tuberculosis (2015)

  431. GUlf States

  432. FLYER: TAG symposium: Scale Up to Get Down to Zero TB deaths, new infections, and suffering

  433. Johns Hopkins response re: intellectual property rights to sutezolid

  434. Report of the Joint TB Monitoring Mission, India, 2015

  435. Use of standardised patients to assess quality of tuberculosis care: a pilot, cross-sectional study

  436. Letter to President TB National Action Plan

  437. India: As healthcare workers die of TB - physicians, health organisations, TB groups, public health experts, and associations of healthcare workers - call for urgent action

  438. Postdoctoral fellowship in tuberculosis diagnostic research

  439. Sample File 3

  440. Prioritizing human rights in the Global Plan to Stop TB 2016-2020

  441. Research in diagnostics for tuberculosis: fundamentals, best practices, and priorities

  442. Appeal to develop VXc-486 for tuberculosis

  443. TB case detection in India: Urgent need to scale up Rapid TB Test Machines and cartridges

  444. Chao Center Reacquires Rights to Cycloserine

  445. Urgent need to scale up access to new treatment options for MDR-TB in the Philippines

  446. WHO: Checklist for periodic evaluation of TB infection control in health-care facilities

  447. Open letter to the Board and Executive Director of the Global Fund

  448. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries

  449. Janssen letter to TB CAB re. compassionate use

  450. CSO letter ldc extension

  451. bedaquiline

  452. linezolid

  453. rifapentine

  454. delamanid

  455. Newest MDR-TB drug prices could fall by up to 95% through generic production

  456. Essential medicines are still essential

  457. Patient support interventions to improve adherence to drug-resistant tuberculosis treatment: A counselling toolkit

  458. Treatment Action Group response letter from Sandoz 29 October 2015

  459. WHO publication: Active tuberculosis drug-safety monitoring and management (aDSM)

  460. New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid

  461. TB CAB Meeting Report_May2015_NYC_External

  462. Global Action Framework for TB Research

  463. Research for TB Elimination team

  464. GeneXpert TB test

  465. GeneXpert TB test free

  466. Call to action on addressing TB in women living with HIV

  467. Urgent need to register quality generic versions of linezolid in South Africa

  468. Annex 1

  469. Annex 2

  470. Annex 3

  471. GCTA launch of the Time for TB campaign

  472. Data for action: collection and use of local data to end tuberculosis

  473. Turning off the tap

  474. Controlling the seedbeds of tuberculosis

  475. Stopping tuberculosis

  476. Tuberculosis—getting to zero

  477. Stopping the body count

  478. No one with HIV should die from tuberculosis

  479. How can we reduce the global burden of disease

  480. Association between spending on social protection and tuberculosis burden: a global analysis

  481. Call for applications to vacant position on the Core Group of the Global Drug-resistant TB Initiative

  482. Open letter to Glenmark regarding registration and pricing of linezolid in South Africa

  483. Open letter to Hetero and Sanofi regarding pricing of linezolid in South Africa

  484. Open letter to Macleods regarding registration and pricing of linezolid in South Africa

  485. Open letter to Pfizer regarding pricing and availability of linezolid in South Africa

  486. Open letter to Teva regarding registration and pricing of linezolid in South Africa

  487. Open letter to Alkem regarding registration and pricing of linezolid in South Africa

  488. Open letter to Amneal regarding registration and pricing of linezolid in South Africa

  489. Open letter to Apotex regarding registration and pricing of linezolid in South Africa

  490. Access to effective antimicrobials: a worldwide challenge

  491. Understanding the mechanisms and drivers of antimicrobial resistance

  492. Maximising access to achieve appropriate human antimicrobial use in low-income and middle-income countries

  493. Antibiotics: achieving the balance between access and excess

  494. Animal production and antimicrobial resistance in the clinic

  495. National action for global gains in antimicrobial resistance

  496. Exploring the evidence base for national and regional policy interventions to combat resistance

  497. International cooperation to improve access to and sustain effectiveness of antimicrobials

  498. NICE guideline on TB treatment and prevention (2016)

  499. Field Implementation Coordinator

  500. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study

  501. Using existing data to illustrate—and close—the gap in access to new anti-tuberculosis drugs

  502. U.S. Senators appeal to President Obama for TB plan funding

  503. Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study

  504. The tuberculosis emergency in eastern Europe

  505. TORs U-CAP

  506. Inclusion of rifapentine in the Global Drug Facility catalogue

  507. GLI Core Group: Call for applications

  508. Update on the use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis

  509. Labor-HHS-Education Subcommittee

  510. Defense Subcommittee

  511. Labor-HHS-Education Subcommittee House

  512. Labor-HHS-Education Subcommittee Senate

  513. Subcommittee on State, Foreign Operations

  514. Subcommittee on State, Foreign Operations 2

  515. Labor-HHS-Education Subcommittee

  516. Consolidated guidelines: Integrating collaborative TB and HIV services within a comprehensive package of care for people who inject drugs

  517. Consultant post for the TB/HIV and community engagement unit of Global TB Programme of WHO

  518. LAM RSA letter from community

  519. U.S. Preventive Services Task Force issues draft recommendation statement on screening for latent tuberculosis infection

  520. Handbook on TB laboratory diagnostic methods for the European Union

  521. Changing the game for multidrug-resistant tuberculosis

  522. Why are people living with HIV still dying of tuberculosis?

  523. A breakthrough urine-based diagnostic test for HIV-associated tuberculosis

  524. WHO Civil Society Task Force on TB

  525. Unmask Stigma

  526. Public health and international drug policy

  527. Eye examination for early diagnosis of disseminated tuberculosis in patients with AIDS

  528. A blood RNA signature for tuberculosis disease risk

  529. Predicting active tuberculosis progression by RNA analysis

  530. Tackling tuberculosis in migrants

  531. Prevalence of and risk factors for active tuberculosis in migrants screened before entry to the UK

  532. Advocates call for WHO to update Delamanid Guidance to include children

  533. Advocates, alarmed by appalling global response to MDR-TB outbreak in Papua New Guinea, call on international agencies to take action

  534. Checklist

  535. National TB Programme of PNG for MDR-TB

  536. WHO joint response

  537. Webinar: Affordability and access to medicines

  538. Agenda

  539. World Health Organization recommends shorter treatment for multidrug-resistant TB

  540. Jim O’Neill presents final international recommendations for the world to defeat superbugs

  541. Introduction of new drugs and drug regimens for the management of drug-resistant tuberculosis in South Africa: policy framework version 1.1

  542. WHO treatment guidelines for drug-resistant tuberculosis: 2016 update (2016)

  543. TB CAB meeting report, Barcelona 2014

  544. TB CAB meeting report, Cape Town 2015

  545. Advocates commend Johns Hopkins University for pursuing a public health driven path for sutezolid’s development

  546. Call for Applications for CSO/CBO/patient representatives to serve on rGLC WHO Western Pacific Region

  547. TB HIV Networking Zone

  548. Enhancing the role of pharmacists in the cascade of tuberculosis care

  549. TB Treatment Trials Grid 2016

  550. Vacancy: Consultant post for the TB/HIV and community engagement unit of Global TB Programme of WHO

  551. Civil Society and Communities Declaration to End HIV: Human Rights Must Come First

  552. Guidelines for the examination of patent applications relating to pharmaceuticals

  553. WHO recommendations on shorter treatment of multidrug-resistant tuberculosis

  554. Call to Action to accelerate access to DR-TB drugs: 2016 update

  555. Advocates call for the Ministry of Health in Cote d’Ivoire to adopt new TB test - ENG

  556. Advocates call for the Ministry of Health in Cote d’Ivoire to adopt new TB test - french

  557. Prevalence of pulmonary tuberculosis in western China in 2010–11: a population-based, cross-sectional survey

  558. New challenges for tuberculosis control in China

  559. Activists call for withdrawal of substandard TB test from India

  560. Call for applications: Eastern Mediterranean Regional Green Light Committee

  561. STEP UP FOR TB - SIGN THE DOTTED LINE

  562. Stephen Lewis' keynote talk at TB 2016 in Durban

  563. Mike Frick's plenary talk at TB2016

  564. Mike Frick's plenary talk at TB2016 slides

  565. TB Alliance Stakeholders Association: Call for community representative

  566. PNG based job opportunities: TB clinicians for 2017

  567. Save the date: "Stop Double Standards" symposium on October 27, 2016

  568. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: Treatment of drug-susceptible TB

  569. WHO policy guidance on the use of TB-LAMP for TB diagnosis

  570. Guidelines on extrapulmonary TB for India

  571. Advocates appeal to the Union Board to host Union World Conferences on Lung Health in high TB burden countries

  572. letter sent to Janssen

  573. letter sent to Otsuka

  574. The Union re: Hosting Union World Conferences on Lung Health in high burden countries

  575. The Union: bid document

  576. "Stop Double Standards" symposium on October 27, 2016

  577. 2017 ARASA call for applications for Training of Trainers Program

  578. Desk-guide for diagnosis and management of TB in children (2016)

  579. Otsuka response 10 October 2016

  580. Call for applications: TB R&D media training

  581. Advocates call for the Ministry of Health in Peru to facilitate access to delamanid, english

  582. Advocates call for the Ministry of Health in Peru to facilitate access to delamanid, spanish

  583. Primer on TB

  584. New TB compound to be developed for Pan-TB regimen

  585. Call to action

  586. Participants list

  587. TB changing flyer

  588. Letter Janssen

  589. Civil society statement following the 47th Union World Conference on Lung Health, Liverpool

  590. Urgent action required to end bureaucratic delays and expedite enrollment of the NExT study

  591. Advocates encourage the establishment of an essential diagnostics list

  592. Location, location, location: tuberculosis services in highest burden countries

  593. ACT Asia-Pacific!

  594. WHO: The use of delamanid in the treatment of MRD-TB in children and adolescents: Interim policy guidance

  595. Open letter EATG 24 October 2016 - EDL

  596. MSF open letter Global Fund

  597. WHO: Technical assistance for the strengthening of childhood TB case finding and management in Liberia

  598. Civil society statement on medicines regulation

  599. A coalition of Indian activists delivered a statement at the 6th Meeting of the BRICS Health Ministers in New Delhi, 15–16 December 2016

  600. Indian activists

  601. Symposium: Drug-resistant TB: challenges & opportunities

  602. Letter to BRICS Ministers through Health Secretaries

  603. Action Plan to address HIV and TB funding withdrawals in middle income countries

  604. Open letter to Johnson & Johnson on ensuring widespread access to bedaquiline for the treatment of tuberculosis

  605. Advocates call for the Philippines Food and Drug Administration to register delamanid

  606. Advocates encourage prioritization of drug-resistant TB research

  607. Advocates call on the Indian Prime Minister to ensure availability of new TB drugs to combat drug-resistant TB

  608. Advocates encourage Danaher to continue investments in Cepheid’s TB products

  609. Essential medicines for universal health coverage

  610. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis

  611. Time to review treatment of isoniazid-resistant tuberculosis?

  612. Safety and efficacy of the C-Tb skin test to diagnose TB

  613. Advocates maintain pressure on the Ministry of Health to facilitate access to delamanid in Peru

  614. Advocates maintain pressure on the Ministry of Health to facilitate access to delamanid in Peru (spanish)

  615. Call for applications: GCTA Regional Focal Points

  616. India plans to expand access to new TB drug

  617. Advocates call on Sequella to provide open access to sutezolid data

  618. Webinar on TB diagnostics

  619. Advocates call on PEPFAR to roll out LAM test

  620. Urgent need to roll out LAM test for TB in some people with HIV

  621. Damien Foundation Letter

  622. Danaher response

  623. GLI Core Group: Call for applications

  624. Advocates encourage the health authorities in Peru to approve the endTB study

  625. Application form

  626. Terms of reference

  627. DR-TB STAT on WHO bedaquiline recommendations

  628. Cepheid

  629. New plan to end tuberculosis in south and southeast Asia

  630. Reducing global tuberculosis deaths—time for India to step up

  631. Sustaining tuberculosis decline in the UK

  632. Candle Light Vigil held at India Gate in memory of the lives lost to TB

  633. Liverpool TB CAB meeting 2016

  634. Durban TB CAB meeting 2016

  635. Guidelines for treatment of drug-susceptible tuberculosis and patient care

  636. webinars

  637. workshop

  638. Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis

  639. TB Treatment Trials Grid 2017

  640. Delamanid letter

  641. Regional capacity-building workshop for TB survivors, English

  642. Regional capacity-building workshop for TB survivors, Spanish

  643. Who pays for cooperation in global health?

  644. Letter: Advocates call on Kenyan DLTLD to adopt new TB test

  645. TB CAB position paper XDR-TB

  646. Vacancy: TB Advocacy Officer, MSF Access Campaign

  647. Bedaquiline or delamanid for rifampin-resistant tuberculosis?

  648. memo tb

  649. Advocates call on Indian authorities to ensure immediate access to delamanid

  650. Symposium: Reframing risk and accountability for action to zero TB

  651. Job profile

  652. Report: TB medicine crisis in Romania

  653. Mileni letter

  654. Letter english

  655. letter spanish

  656. Compendium of WHO guidelines and associated standards: ensuring optimum delivery of the cascade of care for patients with tuberculosis

  657. letter president Kenya

  658. letter CS Kenya

  659. letter India MoH

  660. position paper Kenya

  661. Erica's talk

  662. Romania open letter

  663. flyerf TB course

  664. Submission form eng

  665. Submission form ru

  666. Copyright eng

  667. Copyright ru

  668. open letter TB WHO

  669. Kenya diagnostics

  670. tedros response

  671. kenya dr tedros

  672. WHO position statement on the use of delamanid for multidrug-resistant tuberculosis

  673. Handbook for the use of digital technologies to support tuberculosis medication adherence

  674. letter who guidelines

  675. GeneXpert Omni factsheet

  676. TB CAB position paper bedaquiline

  677. letter who guidelines 07.02.2018

  678. letter who guidelines 20.02.2018

  679. Latent TB Infection: Updated and consolidated guidelines for programmatic management

  680. vaccine

  681. WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis (2018)

  682. GFAN World TB Day Communications Toolkit

  683. Advocates call on Commissioner Andriukaitis to foster EU member states’ response to TB

  684. GLI Core Group: Call for applications

  685. Advocates call on PEPFAR to ensure TB-LAM testing in 2018 COPs

  686. lam pepfar

  687. Position statement on the continued use of the shorter MDR-TB regimen following an expedited review of the STREAM Stage 1 preliminary results

  688. letter who

  689. GDI Core Group: Call for applications

  690. Advocates call for urgent reforms of WHO TB diagnosis and treatment guidelines

  691. Key Asks from TB Stakeholders and Communities Russian

  692. Key Asks from TB Stakeholders and Communities Spanish

  693. Global governance of antimicrobial resistance

  694. UNAIDS side lunch event during the Interactive Civil Society Hearing on TB

  695. Factsheet on TB diagnostics development

  696. Advocates call on Indian Prime Minister to attend the UN High-Level Meeting on TB

  697. Human rights letter

  698. Towards the 2018 UN High-Level Meeting on TB: Recommendations by German civil society organizations

  699. Women & Stigma: Conversations of Resilience in the War Against TB

  700. 5th South African TB Conference, Conference closing session: Closing Remarks by Minister of Health, 15 June 2018

  701. UN HLM on TB Key Ask 1: 40 million by 2022

  702. New bedaquiline data shows reduction in TB mortality cases

  703. Global TB CAB welcomes introduction of safer drug for most South Africans with rifampicin-resistant TB

  704. Special Rapporteur on the Right to Health letter

  705. TB isolation policy

  706. letter Indian Minister of Health

  707. SIRTURO registration

  708. template letter

  709. recommendations

  710. letter page 1

  711. letter page 2

  712. Common African Position on the UN High-Level Meeting on TB

  713. Outcome document of the United Nations meeting on tuberculosis at risk. Germany must not give in to pressure from the US government under Trump

  714. 106 members of U.S. Congress sign letter supporting the UN High-Level Meeting on TB

  715. The TB CAB and TAG welcome WHO recommendation of injectable-free regimens for the treatment of RR/MDR-TB

  716. Urgent need to register essential medicines for the treatment and prevention of TB in South Africa

  717. Handbook on TB laboratory diagnostic methods in the European Union – updated 2018

  718. Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) (2018)

  719. Better and safer treatment for multidrug-resistant TB

  720. HLM Country Statement Checklist

  721. template cover letter

  722. Civil society and affected communities respond to WHO's Global TB Report 2018

  723. UN High-Level Meeting to end tuberculosis disappointing

  724. Advancing global tuberculosis control after the UNGA-HLM

  725. Activists: Call on your countries to use bedaquiline-based regimens to treat TB

  726. WHO and FIND: Technical guide on sequencing

  727. Interim clinical guidance for the implementation of injectable-free regimens for rifampicin-resistant tuberculosis in adults, adolescents and children (2018)

  728. Advocates call on Otsuka to reduce the price of delamanid

  729. Otsuka reply

  730. Rapid shift from global to national purchase of TB drugs increases risk of stockouts and use of drugs of unknown quality

  731. Rapid shift from global to national purchase of TB drugs increases risk of stockouts and use of drugs of unknown quality

  732. Activists call on countries and donors to immediately scale up use of life-saving TB LAM test

  733. Activists urge National TB Programs and treatment providers to discontinue use of harmful injectable agents in TB treatment

  734. Field guide for the management of drug-resistant tuberculosis (2018)

  735. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis (2018)

  736. Nursing Guide for Managing Side Effects to Drug-resistant TB Treatment

  737. Urgent need to address the Global Fund procurement cliff for TB

  738. handout

  739. Call for applications: Steering committee - Declaration on the Rights of People with TB

  740. Call for proposals: Community Representative Grant for TB Drug R&D

  741. Global burden of TB: where we are and what to do

  742. Advocates call on Kenyan government to immediately address dangerous stock out of diagnostic tests for TB

  743. Advocates call on Indian government to improve its response to drug-resistant TB

  744. After the UNGA High-Level Meeting on TB — what next and how?

  745. WHO consolidated guidelines on drug-resistant tuberculosis treatment

  746. WHO guidelines on TB infection prevention and control

  747. Building an Evidence Base to Advocate for TB Research

  748. Call for case studies and good practices on action on TB and comorbidities

  749. Building an Evidence Base to Advocate for TB Research 2

  750. TB CAB statement on M72/AS01E TB vaccine candidate

  751. WHO Platform for community-based TB activities releases its first newsletter

  752. Advocates raise serious concerns about errors in the WHO guidelines for the treatment of drug-resistant TB

  753. Ad-hoc donations of bedaquiline threaten sustainable, affordable access for patients

  754. Call for applications: Consultant to support the WHO Global TB Program Secretariat of the Civil Society Task Force on TB

  755. WHO response

  756. Research, regulatory, and access considerations regarding pretomanid

  757. Tuberculosis: Seminar

  758. Crisis of confidence in the WHO's ability to produce normative guidance for the treatment of RR-/MDR-TB

  759. TAG testimony

  760. TB CAB testimony

  761. NTCA

  762. dr Furin testimony

  763. letter tb alliance

  764. BHIVA guidelines

  765. Management of active tuberculosis in adults with HIV

  766. Transparency and access to pretomanid and the Nix-TB regimen

  767. Practice-based recommendations for the management of RR/MDR-TB

  768. South-East Asia Regional Action Plan on Programmatic Management of Latent Tuberculosis Infection

  769. Webinar: Advancements in TB diagnostics

  770. Call for members: Community Delegation to the Stop TB Partnership Board

  771. Call for members: Developing Country NGO Delegation to the Stop TB Partnership Board

  772. Call for members: Developed Country NGO Delegation to the Stop TB Partnership Board

  773. Time to lower the price of Xpert cartridges to US$ 5

  774. CIVIL SOCIETY DEMANDS AFFORDABILITY, TRANSPARENCY AND ACCOUNTABILITY FROM THE TB ALLIANCE

  775. information note

  776. Civil society statement on rifapentine price discount

  777. Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV

  778. Time to lower the price of Xpert cartridges to US$ 5

  779. ATS, CDC, ERS and IDSA publish new clinical guideline for the treatment and prevention of drug-resistant TB

  780. Multidrug-resistant tuberculosis in children and adolescents in the WHO European Region

  781. TB Alliance, response, pretomanid

  782. Developed Country NGO BM & ABM Call for Nominations 2019

  783. Open Letter to Cepheid - Time to Lower the Price of Xpert Cartridges to US$5 - 6 Jan 2020

  784. press release g-finder 2019

  785. terms of reference

  786. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020

  787. Rapid Communication on forthcoming changes to the programmatic management of tuberculosis preventive treatment

  788. Letter Cepheid - TAG_April 4 2020

  789. Civil society call for equitable and affordable access to COVID-19 and related diagnostics

  790. RCC-THV: Call to action in response to COVID-19

  791. TB CAB Statement

  792. Rapid diagnostics for TB detection

  793. Rapid diagnostics for TB detection, handbook

  794. Drug-resistant TB treatment

  795. Drug-resistant TB treatment, handbook

  796. Applications for Community Connect Track Leads

  797. Declaration of the Rights of People Affected by TB, Arabic

  798. TBpeople: Vacancy assistant position

  799. The European Investment Bank provides €30 million loan to accelerate TB vaccine development

  800. TB affected community & civil society priorities for new Global AIDS Strategy

  801. Cepheid Xpert MTB/RIF Communication September 2011

  802. who instruction

  803. Tuberculosis and COVID-19: an overview of two health emergencies

  804. 2021-2024 TB CAB Membership Application

  805. Letter to NACO CTD for TPT in India

  806. Advocates request Cepheid increase access to GeneXpert SARS-CoV-2 tests in LMICs

  807. TBWomen launch

  808. Screening guidelines

  809. TAG response_March2021

  810. OPEN LETTER- Urgent appeal to improve access to GeneXpert and other diagnostics

  811. TPT Fundamentals for Activists - Flyer 2021

  812. WHO operational handbook on tuberculosis, Module 2: Screening - Systematic screening for tuberculosis disease (2021)

  813. Psychosocial counselling and treatment adherence support for people affected by tuberculosis

  814. Guidance for the surveillance of drug resistance in tuberculosis: Sixth edition

  815. CSO_Response_2021.05.21

  816. Vacancy: STBP Affected Communities Delegation - Advocacy Officer

  817. Call for applications: Constituency Focal Point for the Developed Country NGO Delegation to Global Fund Board

  818. Call for applications: Short Term Consultancy with GCTA

  819. Time for $5 Coalition open letter

  820. Treatment of drug-susceptible tuberculosis: rapid communication

  821. Community engagement lessons learned: A community perspective

  822. WHO operational handbook on tuberculosis. Module 3: Diagnosis - Rapid diagnostics for tuberculosis detection 2021 update

  823. WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis - Rapid diagnostics for tuberculosis detection 2021 update

  824. Advocates ring the alarm on TB medicines and diagnostics stock outs across India

  825. International support for compulsory license to address access barriers to life-saving TB medicines

  826. Advocates urge Cepheid to reinstate plans to commercialize GeneXpert Omni

  827. Stop TB Partnership: Official side-event at Tokyo Nutrition for Growth Summit 2021

  828. Global launch of Learnings, Best Practices and Challenges on TB Stigma, Discrimination and Human Rights report

  829. Advocates call on Unitaid to prioritise AIDS deaths and TB treatment in its investment and strategic plans

  830. The journey continues

  831. Advocates call on Indian government to stop using injectable agents for the treatment of drug-resistant TB

  832. Social Justice & the TB Epidemic: It is time to invest in human rights

  833. Advocates demand immediate national roll out of 3HP in India

  834. The Lancet: Growing concern over Ukrainian refugee health

  835. The Lancet: Seeking accountablity for Ukraine health-care attacks

  836. Invest in women to end TB – Where women lead, change happens

  837. Table

  838. DS-TB WHO guidelines

  839. DS-TB WHO handbook

  840. WHO guidelines pediatrics

  841. WHO handbook pediatrics

  842. Manual for selection of molecular WHO recommended rapid diagnostic tests for detection of TB and DR-TB

  843. Practical manual of processing stool samples for diagnosis of childhood TB

  844. Line probe assays for detection of DR-TB

  845. TB legislation ENG

  846. TB legislation RU

  847. Joint statement

  848. Forum invitation

  849. Cocept note

  850. Declaration of the Rights of People Affected by TB

  851. Indian letter

  852. TB care and support, guidelines

  853. TB care and support, handbook

  854. TB CAB 10-year anniversary evaluation report 2011–2021

  855. Advocates reiterate its demand for immediate national roll out of 3HP in India

  856. WHO operational handbook on tuberculosis. Module 3: Diagnosis - Tests for tuberculosis infection

  857. WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis – Tests for tuberculosis infection

  858. Updates required to the National TB guidelines to support access to shorter regimens as a human right in India

  859. 1/4/6x24 Campaign call to action at the USAID TB Symposium

  860. Response to Tuberculosis Treatment Trials Results Published and Presented During the 2022 Union World Conference on Lung Health

  861. Manual on selection and use of interferon-gamma release assays (IGRAs) for testing for TB infection

  862. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update

  863. WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update

  864. Manual on selection and use of interferon-gamma release assays (IGRAs) for testing for TB infection (2022)

  865. Urgent action necessary to improve equitable access to bedaquiline-based regiments and achieve 1/4/6×24

  866. Practical manual on laboratory strengthening (2022)

  867. Webinar: What's new in childhood TB

  868. Priority TB community, rights & gender interventions for inclusion in Global Fund applications 2023-2025

  869. Diagnosis and Management of Tuberculosis in Children and Adolescents: A Desk Guide for Primary Health Care Workers - Asia (2023)

  870. Diagnosis and Management of Tuberculosis in Children and Adolescents: A Desk Guide for Primary Health Care Workers - Africa (2023)

  871. Urgent action necessary to improve equitable access to GeneXpert TB diagnostics and achieve 1/4/6x24

  872. ECDC-WHO/Europe World TB Day webinar

  873. Fast-tracking progress to End TB: high-level opportunities for investment and action

  874. Joint statement

  875. Call to action

  876. Newsletter

  877. flyer

  878. Vax CAB 2023 roadmap

  879. Use of delamanid in children and adolescents with multidrug- and rifampicin-resistant tuberculosis: information note (2023)

  880. Use of bedaquiline in children and adolescents with multidrug- and rifampicin-resistant tuberculosis: information note (2023)

  881. Urgent action necessary for equitable access to bedaquiline in all countries with high burdens of TB, MDR-TB, and TB/HIV

  882. Member States must commit to invest in TB vaccine R&D

  883. Open letter to Johnson & Johnson requesting clarification on the recent deal on generic bedaquiline supply

  884. WHO operational handbook on tuberculosis: module 1: prevention: infection prevention and control

  885. WHO consolidated guidelines on tuberculosis: Module 1: Prevention - infection prevention and control

  886. webinar

  887. flyer survey

  888. Webinar: Time for $5 Campaign update